B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition; the invention provides humanized CD37-specific binding molecules.
1 .- 117 . (canceled)
118 . A humanized or chimeric CD37-specific binding molecule comprising a binding domain and immunoglobulin CH2 and CH3 domains, wherein the binding domain comprises:
a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 61;
a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 64;
a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 66;
a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 63;
a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 65; and
a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 67 or 68.
119 . A pharmaceutical composition comprising a humanized or chimeric CD37-specific binding molecule and one or more pharmaceutically acceptable carriers or additives, wherein the CD37-specific binding molecule comprises a binding domain and immunoglobulin CH2 and CH3 domains, wherein the binding domain comprises:
a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 61;
a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 64;
a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 66;
a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 63;
a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 65; and
a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 67 or 68.